[Bench-test evaluation of spacer devices for fluticasone delivery to infants].

[1]  J. Dubus,et al.  [Critical evaluation of inhalation spacer devices available in France]. , 2015, Revue des maladies respiratoires.

[2]  M. Newhouse,et al.  Nasal versus oral aerosol delivery to the “lungs” in infants and toddlers , 2015, Pediatric pulmonology.

[3]  S. Davis,et al.  Breathing easier: addressing the challenges of aerosolizing medications to infants and preschoolers. , 2014, Respiratory medicine.

[4]  GolshahiLaleh,et al.  Pediatric In Vitro and In Silico Models of Deposition via Oral and Nasal Inhalation , 2014 .

[5]  R. Mehta,et al.  Bioavailability of inhaled fluticasone propionate via chambers/masks in young children , 2011, European Respiratory Journal.

[6]  R. Tepper,et al.  Effect of inhaled fluticasone on lung function in infants with recurrent wheezing: a randomised controlled trial. , 2009, Allergologia et immunopathologia.

[7]  P. Sly,et al.  Physiology: the basis of normal function yet too often ignored , 2006 .

[8]  A. Teper,et al.  Fluticasone improves pulmonary function in children under 2 years old with risk factors for asthma. , 2005, American journal of respiratory and critical care medicine.

[9]  W. Hop,et al.  Efficacy of fluticasone propionate on lung function and symptoms in wheezy infants. , 2005, American journal of respiratory and critical care medicine.

[10]  I. Bergadá,et al.  Effects of inhaled fluticasone propionate in children less than 2 years old with recurrent wheezing , 2004, Pediatric pulmonology.

[11]  P. Seddon,et al.  Persistent wheezing in infants with an atopic tendency responds to inhaled fluticasone , 2001, Archives of disease in childhood.

[12]  H. Tiddens,et al.  Aerosol therapy: the special needs of young children. , 2006, Paediatric respiratory reviews.